Our portfolio of 15 approved medicines reflects our deep understanding of the wants and needs of the HIV community. We’re proud to have led the way in transformational HIV medicines, but we’re not done yet. We know there isn’t a ‘one size fits all’ solution to treating, preventing or even curing HIV – that’s why our scientists, based at dedicated labs in Branford, Connecticut and Durham, North Carolina are committed to developing the next-generation of HIV innovation driven by unmet need and unparalleled patient insights. You can find out more about our research and innovation here.

Alongside our novel approach to R&D, we’re committed to powerful partnerships that drive impact at scale. Key to this is increasing access to medicines and reaching those most impacted by HIV, no matter who they are or where they live. We do this through responsible pricing, sharing intellectual property and cross-sector collaboration working hand-in-hand with organisations like IAS, CHAI and MPP. As an example, our voluntary licence agreements allow generic manufacturers to develop paediatric formulations of our medicines where 99% of children living with HIV live.

Across the world, persistent stigma and harmful misinformation threaten to undermine progress. That’s why we work with, partner and invest in the community and key stakeholders to tackle HIV-related challenges and support the most vulnerable. For example, through our Positive Action programme, we work directly with grassroot organisations to co-create solutions that strengthen healthcare systems and create healthier communities. You can find out more about our work with the community here.